key: cord-0845621-pmrip22t
authors: Price, Elizabeth; Treacher, David F.
title: Reduced gastric acidity, proton pump inhibitors and increased severity of COVID-19 infections
date: 2021-02-18
journal: Crit Care
DOI: 10.1186/s13054-021-03497-6
sha: 2ba31754a03426a04ce4a353f09881b2f7422840
doc_id: 845621
cord_uid: pmrip22t

nan

There are now articles linking the use of proton pump inhibitors (PPIs) to an increased risk of more severe COVID-19 infections [1, 2] . As discussed in our research letter [3] , this is not surprising because these viruses can be swallowed and may spread via the gastrointestinal tract as well as the respiratory tract. Gastric acid is a partial barrier which restricts the entry of SARS-CoV-2 viruses into the rest of the gastrointestinal tract. This acid barrier is removed by a single dose of a PPI, as it raises the gastric pH from its usual level of 1.5 -3.5 to over 6.0. At this less acid pH, these viruses are not inactivated [3, 4] . This may be part of the reason young people and children rarely get a severe COVID-19 illness, as this age group usually has good gastric acidity.

For ventilated patients, as well as the PPI risk, continuous nasogastric feeding regimes may present a risk of a more severe COVID-19 illness. For patients on these continuous regimes, the gastric pH will be around 4.0 or 5.0. At this pH, SARS-CoV-2 viruses will not be inactivated [3, 4] . In contrast, intermittent nasogastric feeding will allow the gastric pH to fall to < 2.0 between periods of feeding. At this more acid pH level, the viruses could be inactivated.

During the present pandemic, it would be useful if a risk-benefit assessment could be carried out for patients on PPIs. A histamine-2 receptor antagonist (sometimes specified as famotidine) has been mentioned as a possible alternative but further review is needed [2, 5] . In addition, maintaining gastric acidity in ventilated COVID-19 patients by intermittent nasogastric feeding, could be considered where possible.

research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year • At BMC, research is always in progress. Learn more biomedcentral.com/submissions Ready to submit your research Ready to submit your research ? Choose BMC and benefit from: ? Choose BMC and benefit from: propensity score matching

Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection. Dig Liver Dis

Could the severity of COVID-19 be increased by low acidity? Critical Care

Factors affecting stability and infectivity of SARS-CoV-2

Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

We acknowledge the advice of the following: Dr Richard Cunningham MB FRCPath, Professor John Walker-Smith MD FRCP FRACP FRCHCH